Update on CMV and Treatment Options for 2022

Aliyah Baluch, MD
Aliyah Baluch, MD, Msc
Thursday, May 19, 2022
Category: Immunocompromised Host, Infectious in Oncology, Transplant Infectious Diseases, Viral Infections

Dr. Aliyah Baluch, Program Director of the Infectious Diseases Transplant Program at the Moffitt Cancer Center and Research Institute, presents an update on CMV infections in the Immunocompromised host. She begins by discussing the basics of allogeneic stem cell transplantation, including pre-transplant screening and what differentiates a “high risk transplant.” She then provides some background information on Cytomegalovirus, including its clinical manifestations in susceptible patients. Next, Dr. Baluch conveys the phases of infection in stem cell transplant, and identifies the high risk period for CMV disease to typically occur. She then discusses CMV diagnosis, antiviral therapies, and CMV prophylaxis strategies. Dr. Baluch closes by discussing CMV drug resistance as well as several information resources useful in the management of CMV-infected patients.

Stay in touch! Download our app in the iTunes store or the Google Marketplace.